Palvella Therapeutics (PVLA) Research & Development (2014 - 2026)
Palvella Therapeutics (PVLA) reported Research & Development of $9.3 million for Q1 2026, up 129.11% year-over-year from $4.1 million in Q1 2025, and up 31.08% quarter-over-quarter from $7.1 million in Q4 2025.
Palvella Therapeutics (PVLA) Research & Development (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Research & Development data on file, last reported at $9.3 million in Q1 2026.
- Research & Development for Q1 2026 came in at $9.3 million, up 129.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.1 million (up 149.99% YoY), and the FY2025 annual result was $22.8 million, up 180.22% from the prior year.
- Research & Development improved to $9.3 million in Q1 2026 per PVLA's latest filing, from $7.1 million in the prior quarter.
- Over five years, Research & Development peaked at $14.3 million in Q2 2023 and troughed at -$28.6 million in Q4 2023.
- A 5-year average of $5.5 million and a median of $6.8 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development slumped 92.67% in 2024, then jumped 314.02% in 2025.
- A 5-year view of Research & Development shows it stood at $13.6 million in 2022, then plunged by 310.13% to -$28.6 million in 2023, then soared by 108.91% to $2.5 million in 2024, then surged by 180.02% to $7.1 million in 2025, then soared by 31.08% to $9.3 million in 2026.
- Business Quant data shows PVLA's Research & Development at $9.3 million in Q1 2026, $7.1 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | 9.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.33 Mn |
| Dec 31, 2025 | 7.12 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.07 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 984,000.00 |
| Dec 31, 2023 | -28.55 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 14.33 Mn |
| Mar 31, 2023 | 13.42 Mn |
| Sep 30, 2022 | 13.59 Mn |
| Jun 30, 2022 | 11.95 Mn |
| Mar 31, 2022 | 14.07 Mn |
| Dec 31, 2021 | 15.36 Mn |
| Sep 30, 2021 | 18.94 Mn |
| Jun 30, 2021 | 15.80 Mn |
| Mar 31, 2021 | 16.56 Mn |